Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:warfarin
go back to main search page
Accession:CHEBI:10033 term browser browse the term
Definition:A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.
Synonyms:exact_synonym: rac-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
 related_synonym: (RS)-Warfarin;   4-hydroxy-3-[(1RS)-3-oxo-1-phenylbutyl]-2H-1-benzopyran-2-one;   4-hydroxy-3-[(1RS)-3-oxo-1-phenylbutyl]-2H-chromen-2-one;   4-hydroxy-3-[(1RS)-3-oxo-1-phenylbutyl]coumarin;   Brumolin;   Coumafene;   DL-3-(alpha-acetonylbenzyl)-4-hydroxycoumarin;   DL-warfarin;   Formula=C19H16O4;   Kumadu;   Kumatox;   Ratron;   Rodafarin;   Warf 10;   Zoocoumarin;   rac-1-(4'-hydroxy-3'-coumarinyl)-1-phenyl-3-butanone;   rac-3-(1'-phenyl-2'-acetylethyl)-4-hydroxycoumarin;   rac-3-(acetonylbenzyl)-4-hydroxycoumarin;   rac-3-(alpha-acetonylbenzyl)-4-hydroxycoumarin;   rac-3-(alpha-phenyl-beta-acetylethyl)-4-hydroxycoumarin;   rac-4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin;   rac-warfarin;   racemic warfarin;   warfarina;   warfarine;   warfarinum
 xref: CAS:81-81-2;   DrugBank:DB00682;   FooDB:FDB022750;   HMDB:HMDB0001935;   KEGG:C01541;   KEGG:D08682;   LINCS:LSM-1405
 xref_mesh: MESH:D014859
 xref: PMCID:PMC10207235;   PMID:13358873;   PMID:15578879;   PMID:18294321;   PMID:19294412;   PMID:24478171;   PMID:24973057;   PMID:25022924;   PMID:25023204;   PMID:25393417;   PMID:25466603;   PMID:25534862;   PMID:25537751;   PMID:25555316;   PMID:25683623;   PMID:25757926;   PMID:25823787;   PMID:25828628;   PMID:25830869;   PMID:25842804;   PMID:25845131;   PMID:25986145;   PMID:26114209;   PMID:26142522;   PMID:26142525;   PMID:26203765;   PMID:26238769;   PMID:37359384;   PMID:37648560;   PMID:37755126;   PPDB:681;   Patent:US2427578;   Patent:US2765321;   Patent:US2777859;   Patent:US3239529;   Pesticides:warfarin;   Reaxys:1293536;   Wikipedia:Warfarin
 cyclic_relationship: is_conjugate_acid_of CHEBI:50393


show annotations for term's descendants           Sort by:
warfarin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 affects response to substance
increases expression		 EXP
ISO		 ABCB1 polymorphism affects the susceptibility to Warfarin
Warfarin results in increased expression of ABCB1A mRNA		 CTD PMID:24092646 PMID:25312789 PMID:27397090 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323 		JBrowse link
G ABCC6 ATP binding cassette subfamily C member 6 multiple interactions
increases response to substance		 ISO [Magnesium deficiency co-treated with Phosphates] promotes the reaction [ABCC6 gene mutant form results in increased susceptibility to Warfarin] CTD PMID:23415960 NCBI chr16:16,149,565...16,223,494
Ensembl chr16:16,149,565...16,223,522 		JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (JR blood group) affects response to substance EXP ABCG2 SNP affects the susceptibility to Warfarin CTD PMID:25300812 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628 		JBrowse link
G ACTA2 actin alpha 2, smooth muscle multiple interactions ISO [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of ACTA2 mRNA CTD PMID:23117658 NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339 		JBrowse link
G ACTB actin beta increases expression
decreases expression		 ISO Warfarin results in increased expression of ACTB mRNA
Warfarin results in decreased expression of ACTB mRNA		 CTD PMID:20493250 NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902 		JBrowse link
G ACTR3 actin related protein 3 increases expression ISO Warfarin results in increased expression of ACTR3 mRNA CTD PMID:20493250 NCBI chr 2:113,889,934...113,962,596
Ensembl chr 2:113,890,063...113,962,596 		JBrowse link
G ADIPOQ adiponectin, C1Q and collagen domain containing increases expression
multiple interactions		 ISO Warfarin results in increased expression of ADIPOQ protein
Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of ADIPOQ protein]		 CTD PMID:27488359 NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463 		JBrowse link
G AGTR1 angiotensin II receptor type 1 multiple interactions EXP epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 mRNA]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 protein] CTD PMID:36162953 NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008 		JBrowse link
G AHCY adenosylhomocysteinase decreases expression ISO Warfarin results in decreased expression of AHCY mRNA CTD PMID:20493250 NCBI chr20:34,231,981...34,311,836
Ensembl chr20:34,280,268...34,311,802 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions ISO 6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP inhibits the reaction [[Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein]; [Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein; [Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein] CTD PMID:22659116 PMID:27212383 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759 		JBrowse link
G ALB albumin multiple interactions
decreases expression
affects binding		 EXP
ISO		 [Warfarin binds to ALB protein] inhibits the reaction [copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) binds to ALB protein]; [Warfarin binds to ALB protein] inhibits the reaction [copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex binds to ALB protein]; Aspirin inhibits the reaction [Warfarin binds to ALB protein]; prodan inhibits the reaction [Warfarin binds to ALB protein]; Pyruvaldehyde inhibits the reaction [Warfarin binds to ALB protein]
Warfarin results in decreased expression of ALB protein		 CTD PMID:10506189 PMID:12044178 PMID:18937368 PMID:19596536 PMID:20934417 More... NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482 		JBrowse link
G ALOX5AP arachidonate 5-lipoxygenase activating protein increases expression EXP Warfarin results in increased expression of ALOX5AP mRNA CTD PMID:16698924 NCBI chr13:30,713,485...30,764,426
Ensembl chr13:30,713,478...30,764,426 		JBrowse link
G ALPL alkaline phosphatase, biomineralization associated multiple interactions ISO Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA] CTD PMID:21910061 NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410 		JBrowse link
G ANXA4 annexin A4 decreases expression ISO Warfarin results in decreased expression of ANXA4 mRNA CTD PMID:20493250 NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112 		JBrowse link
G ANXA5 annexin A5 decreases expression ISO Warfarin results in decreased expression of ANXA5 mRNA CTD PMID:20493250 NCBI chr 4:121,667,946...121,696,980
Ensembl chr 4:121,667,946...121,696,995 		JBrowse link
G APOA1 apolipoprotein A1 affects response to substance EXP APOA1 gene SNP affects the susceptibility to Warfarin CTD PMID:32282500 NCBI chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622 		JBrowse link
G APOB apolipoprotein B affects response to substance EXP APOB gene SNP affects the susceptibility to Warfarin CTD PMID:31186542 NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073 		JBrowse link
G APOE apolipoprotein E increases response to substance
affects response to substance		 ISO
EXP		 APOE gene mutant form results in increased susceptibility to Warfarin
APOE gene mutant form affects the susceptibility to Warfarin; APOE gene polymorphism affects the susceptibility to Warfarin; APOE gene SNP affects the susceptibility to Warfarin; APOE polymorphism affects the susceptibility to Warfarin; APOE protein affects the susceptibility to Warfarin; APOE SNP affects the susceptibility to Warfarin		 CTD PMID:15952022 PMID:16847429 PMID:17048007 PMID:17325732 PMID:21228733 More... NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393 		JBrowse link
G ARHGDIA Rho GDP dissociation inhibitor alpha increases expression ISO Warfarin results in increased expression of ARHGDIA mRNA CTD PMID:20493250 NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,719...81,871,378 		JBrowse link
G ARSL arylsulfatase L decreases activity EXP Warfarin results in decreased activity of ARSL protein CTD PMID:7720070 NCBI chr  X:2,934,521...2,968,245
Ensembl chr  X:2,934,045...2,968,475 		JBrowse link
G ASPH aspartate beta-hydroxylase affects response to substance EXP ASPH gene SNP affects the susceptibility to Warfarin CTD PMID:27488176 NCBI chr 8:61,500,556...61,714,592
Ensembl chr 8:61,500,556...61,714,640 		JBrowse link
G AXIN2 axin 2 increases expression
multiple interactions		 ISO Warfarin results in increased expression of AXIN2 mRNA
[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of AXIN2 mRNA]		 CTD PMID:23117658 NCBI chr17:65,528,563...65,561,648
Ensembl chr17:65,528,563...65,561,648 		JBrowse link
G AXL AXL receptor tyrosine kinase multiple interactions
decreases expression
increases response to substance
decreases phosphorylation		 ISO
EXP		 [Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of AXL protein]
Warfarin results in decreased expression of AXL protein; Warfarin results in decreased expression of AXL protein modified form
AXL protein promotes the reaction [Warfarin results in increased susceptibility to Gemcitabine]; Vitamin K inhibits the reaction [Warfarin results in decreased expression of AXL protein modified form]; Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein]
AXL protein results in increased susceptibility to Warfarin
Warfarin results in decreased phosphorylation of AXL protein		 CTD PMID:15123721 PMID:26206560 PMID:27212383 NCBI chr19:41,219,223...41,261,766
Ensembl chr19:41,219,223...41,261,766 		JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions ISO [Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein] CTD PMID:27212383 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BGLAP bone gamma-carboxyglutamate protein multiple interactions
increases expression		 ISO Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [menaquinone 7 results in increased carboxylation of BGLAP protein]; Warfarin inhibits the reaction [menatetrenone results in increased carboxylation of BGLAP protein]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [Vitamin K 1 results in increased carboxylation of BGLAP protein]
[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of BGLAP protein modified form]
Warfarin results in increased expression of BGLAP mRNA; Warfarin results in increased expression of BGLAP protein modified form		 CTD PMID:21910061 PMID:23117658 PMID:23223575 PMID:27488359 PMID:31173816 NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317 		JBrowse link
G BMP2 bone morphogenetic protein 2 multiple interactions ISO Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]
[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein]		 CTD PMID:21910061 PMID:27412937 NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246 		JBrowse link
G C1QBP complement C1q binding protein increases expression ISO Warfarin results in increased expression of C1QBP mRNA CTD PMID:20493250 NCBI chr17:5,432,777...5,439,155
Ensembl chr17:5,432,777...5,448,830 		JBrowse link
G CALR calreticulin increases expression ISO Warfarin results in increased expression of CALR mRNA CTD PMID:20493250 NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489 		JBrowse link
G CALU calumenin decreases response to substance
affects response to substance		 ISO
EXP		 CALU protein results in decreased susceptibility to Warfarin
CALU gene SNP affects the susceptibility to Warfarin; CALU polymorphism affects the susceptibility to Warfarin		 CTD PMID:11641264 PMID:20200517 PMID:27632229 NCBI chr 7:128,739,359...128,773,400
Ensembl chr 7:128,739,292...128,773,400 		JBrowse link
G CASP3 caspase 3 decreases expression
increases expression
multiple interactions		 ISO
EXP		 Warfarin results in decreased expression of CASP3 mRNA
Warfarin results in increased expression of CASP3 mRNA
[Warfarin co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein
Warfarin results in increased expression of CASP3 protein modified form		 CTD PMID:19815060 PMID:20493250 PMID:23990204 PMID:26206560 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CAT catalase increases activity ISO Warfarin results in increased activity of CAT protein CTD PMID:22342526 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCND1 cyclin D1 multiple interactions
increases expression		 ISO [Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of CCND1 mRNA] CTD PMID:23117658 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CCT5 chaperonin containing TCP1 subunit 5 increases expression ISO Warfarin results in increased expression of CCT5 mRNA CTD PMID:20493250 NCBI chr 5:10,249,921...10,266,412
Ensembl chr 5:10,249,929...10,266,389 		JBrowse link
G CCT6A chaperonin containing TCP1 subunit 6A increases expression ISO Warfarin results in increased expression of CCT6A mRNA CTD PMID:20493250 NCBI chr 7:56,051,765...56,063,989
Ensembl chr 7:56,051,685...56,063,989 		JBrowse link
G CCT8 chaperonin containing TCP1 subunit 8 decreases expression ISO Warfarin results in decreased expression of CCT8 mRNA CTD PMID:20493250 NCBI chr21:29,056,326...29,073,648
Ensembl chr21:29,055,805...29,073,797 		JBrowse link
G CDC42 cell division cycle 42 decreases expression ISO Warfarin results in decreased expression of CDC42 mRNA CTD PMID:20493250 NCBI chr 1:22,052,709...22,101,360
Ensembl chr 1:22,052,627...22,101,360 		JBrowse link
G CDH1 cadherin 1 increases expression EXP Warfarin results in increased expression of CDH1 protein CTD PMID:26206560 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537 		JBrowse link
G CLIC1 chloride intracellular channel 1 decreases expression ISO Warfarin results in decreased expression of CLIC1 mRNA CTD PMID:20493250 NCBI chr 6:31,730,581...31,737,318
Ensembl chr 6:31,730,581...31,739,763 		JBrowse link
G CNN1 calponin 1 multiple interactions ISO [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of CNN1 mRNA CTD PMID:23117658 NCBI chr19:11,538,851...11,550,323
Ensembl chr19:11,538,767...11,550,323 		JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions
increases expression		 ISO Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]
[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of COL1A1 mRNA]		 CTD PMID:21910061 PMID:23117658 PMID:23223575 NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632 		JBrowse link
G COX15 cytochrome c oxidase assembly homolog COX15 affects response to substance EXP COX15 gene affects the susceptibility to Warfarin CTD PMID:28686080 NCBI chr10:99,694,293...99,732,127
Ensembl chr10:99,710,868...99,732,127 		JBrowse link
G COX5A cytochrome c oxidase subunit 5A increases expression ISO Warfarin results in increased expression of COX5A mRNA CTD PMID:20493250 NCBI chr15:74,919,791...74,938,073
Ensembl chr15:74,919,791...74,938,083 		JBrowse link
G CRK CRK proto-oncogene, adaptor protein increases expression ISO Warfarin results in increased expression of CRK mRNA CTD PMID:20493250 NCBI chr17:1,420,693...1,456,232
Ensembl chr17:1,420,689...1,463,162 		JBrowse link
G CTNNB1 catenin beta 1 multiple interactions
affects response to substance		 EXP
ISO		 Warfarin results in decreased expression of and affects the localization of CTNNB1 protein
CTNNB1 protein affects the susceptibility to Warfarin
Quercetin inhibits the reaction [Warfarin results in increased expression of and affects the localization of CTNNB1 protein]; Warfarin results in increased expression of and affects the localization of CTNNB1 protein		 CTD PMID:23117658 PMID:23223575 PMID:26206560 NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Warfarin co-treated with lipopolysaccharide, E. coli O26-B6] results in decreased expression of CXCL8 mRNA CTD PMID:29594315 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 decreases activity ISO Warfarin results in decreased activity of CYP1A1 protein CTD PMID:18420780 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536 		JBrowse link
G CYP1A2 cytochrome P450 family 1 subfamily A member 2 affects metabolic processing
affects response to substance		 EXP CYP1A2 protein affects the metabolism of Warfarin
CYP1A2 SNP affects the susceptibility to Warfarin		 CTD PMID:14676821 PMID:15280511 PMID:28079798 NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607 		JBrowse link
G CYP2A7 cytochrome P450 family 2 subfamily A member 7 decreases activity ISO Warfarin results in decreased activity of CYP2A4 protein CTD PMID:18420780 NCBI chr19:40,875,439...40,882,231
Ensembl chr19:40,875,439...40,882,752 		JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 decreases activity ISO Warfarin results in decreased activity of CYP2B10 protein CTD PMID:18420780 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398 		JBrowse link
G CYP2C18 cytochrome P450 family 2 subfamily C member 18 affects response to substance
increases metabolic processing		 EXP
ISO		 CYP2C18 gene polymorphism affects the susceptibility to Warfarin; CYP2C18 protein affects the susceptibility to Warfarin
CYP2C11 protein results in increased metabolism of Warfarin		 CTD PMID:19752777 PMID:30724651 NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190 		JBrowse link
G CYP2C19 cytochrome P450 family 2 subfamily C member 19 affects response to substance
multiple interactions
affects metabolic processing		 EXP CYP2C19 gene polymorphism affects the susceptibility to Warfarin; CYP2C19 polymorphism affects the susceptibility to Warfarin; CYP2C19 protein affects the susceptibility to Warfarin
CYP2C19 gene polymorphism affects the metabolism of and affects the susceptibility to Warfarin; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin]		 CTD PMID:18520598 PMID:19752777 PMID:25652102 PMID:27356304 NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547 		JBrowse link
G CYP2C8 cytochrome P450 family 2 subfamily C member 8 decreases activity
affects response to substance		 ISO
EXP		 Warfarin results in decreased activity of CYP2C29 protein
CYP2C8 polymorphism affects the susceptibility to Warfarin		 CTD PMID:18420780 PMID:34382722 NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497 		JBrowse link
G CYP2C9 cytochrome P450 family 2 subfamily C member 9 affects metabolic processing
affects hydrolysis
decreases response to substance
decreases hydroxylation
decreases metabolic processing
affects hydroxylation
increases hydrolysis
increases metabolic processing
decreases activity
multiple interactions
affects response to substance
increases response to substance
affects abundance
increases hydroxylation		 EXP CYP2C9 enhancer polymorphism affects the metabolism of Warfarin; CYP2C9 gene affects the metabolism of Warfarin; CYP2C9 gene polymorphism affects the metabolism of Warfarin; CYP2C9 protein affects the metabolism of Warfarin
CYP2C9 gene polymorphism affects the hydrolysis of Warfarin
CYP2C9 gene polymorphism results in decreased susceptibility to Warfarin
CYP2C9 gene polymorphism results in decreased hydroxylation of Warfarin
CYP2C9 gene polymorphism results in decreased metabolism of Warfarin
CYP2C9 protein affects the hydroxylation of Warfarin
CYP2C9 protein results in increased hydrolysis of Warfarin
CYP2C9 protein results in increased metabolism of Warfarin
Warfarin results in decreased activity of CYP2C9 protein
10-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; 4'-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; 6-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; 7-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 6-hydroxywarfarin]; 8-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; [[Ticrynafen results in decreased activity of CYP2C9 protein] which affects the metabolism of Warfarin analog] which affects the abundance of 7-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 10-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 4'-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 6-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 7-hydroxywarfarin; [CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 6-hydroxywarfarin; [CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin; [CYP2C9 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of 6-hydroxywarfarin; [CYP2C9 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin; [Ticrynafen results in decreased activity of CYP2C9 protein] which affects the metabolism of Warfarin analog; [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA; Benzbromarone inhibits the reaction [CYP2C9 protein affects the metabolism of Warfarin]; CYP2C9 gene polymorphism affects the reaction [Vitamin K affects the susceptibility to Warfarin]; CYP2C9 gene polymorphism affects the susceptibility to and affects the metabolism of Warfarin; Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin]; Warfarin inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]
CYP2C9 affects the susceptibility to Warfarin; CYP2C9 alternative form affects the susceptibility to Warfarin; CYP2C9 gene affects the susceptibility to Warfarin; CYP2C9 gene mutant form affects the susceptibility to Warfarin; CYP2C9 gene polymorphism affects the susceptibility to Warfarin; CYP2C9 gene SNP affects the susceptibility to Warfarin; CYP2C9 polymorphism affects the susceptibility to Warfarin; CYP2C9 protein affects the susceptibility to Warfarin; CYP2C9 protein polymorphism affects the susceptibility to Warfarin; CYP2C9 SNP affects the susceptibility to Warfarin; CYP2C9 SNP affects the susceptibility to Warfarin analog
CYP2C9 gene mutant form results in increased susceptibility to Warfarin; CYP2C9 gene polymorphism results in increased susceptibility to Warfarin; CYP2C9 protein results in increased susceptibility to Warfarin; CYP2C9 results in increased susceptibility to Warfarin
CYP2C9 gene polymorphism affects the abundance of Warfarin		 CTD PMID:9241660 PMID:9522436 PMID:9698079 PMID:10613612 PMID:11127854 More... NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091 		JBrowse link
G CYP2D6 cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene) decreases activity EXP Warfarin results in decreased activity of CYP2D6 protein CTD PMID:18420780 NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865 		JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 decreases activity
affects metabolic processing
multiple interactions
affects hydroxylation
affects response to substance
decreases expression
increases expression		 EXP
ISO		 Warfarin results in decreased activity of CYP3A4 protein
CYP3A4 protein affects the metabolism of Warfarin
[Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
CYP3A4 protein affects the hydroxylation of Warfarin
CYP3A4 SNP affects the susceptibility to Warfarin
Warfarin results in decreased expression of CYP3A4 mRNA
CYP3A2 mRNA affects the susceptibility to Warfarin
Warfarin results in increased expression of CYP3A2 mRNA		 CTD PMID:2271712 PMID:11531004 PMID:15280511 PMID:16035367 PMID:18420780 More... NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248 		JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 affects response to substance EXP CYP3A5 gene polymorphism affects the susceptibility to Warfarin; CYP3A5 polymorphism affects the susceptibility to Warfarin; CYP3A5 protein affects the susceptibility to Warfarin CTD PMID:19752777 PMID:34382722 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996 		JBrowse link
G CYP4F2 cytochrome P450 family 4 subfamily F member 2 multiple interactions
increases response to substance
affects response to substance		 EXP [CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin
CYP4F2 protein results in increased susceptibility to Warfarin
CYP4F2 gene affects the susceptibility to Warfarin; CYP4F2 gene mutant form affects the susceptibility to Warfarin; CYP4F2 gene polymorphism affects the susceptibility to Warfarin; CYP4F2 gene SNP affects the susceptibility to Warfarin; CYP4F2 polymorphism affects the susceptibility to Warfarin; CYP4F2 protein polymorphism affects the susceptibility to Warfarin; CYP4F2 SNP affects the susceptibility to Warfarin		 CTD PMID:18250228 PMID:19207028 PMID:19270263 PMID:19300499 PMID:20217574 More... NCBI chr19:15,878,023...15,898,074
Ensembl chr19:15,878,023...15,898,077 		JBrowse link
G DCTN2 dynactin subunit 2 decreases expression ISO Warfarin results in decreased expression of DCTN2 mRNA CTD PMID:20493250 NCBI chr12:57,530,051...57,547,192
Ensembl chr12:57,529,633...57,547,224 		JBrowse link
G DDHD1 DDHD domain containing 1 affects response to substance EXP DDHD1 gene SNP affects the susceptibility to Warfarin CTD PMID:27488176 NCBI chr14:53,036,755...53,153,323
Ensembl chr14:53,036,745...53,153,323 		JBrowse link
G DDT D-dopachrome tautomerase decreases expression ISO Warfarin results in decreased expression of DDT mRNA CTD PMID:20493250 NCBI chr22:23,971,370...23,980,504
Ensembl chr22:23,970,542...23,980,525 		JBrowse link
G DLST dihydrolipoamide S-succinyltransferase decreases expression ISO Warfarin results in decreased expression of DLST mRNA CTD PMID:20493250 NCBI chr14:74,881,916...74,903,743
Ensembl chr14:74,881,891...74,903,743 		JBrowse link
G DOCK7 dedicator of cytokinesis 7 increases expression ISO Warfarin results in increased expression of DOCK7 mRNA CTD PMID:20493250 NCBI chr 1:62,454,726...62,688,386
Ensembl chr 1:62,454,298...62,688,386 		JBrowse link
G DPYSL2 dihydropyrimidinase like 2 increases expression ISO Warfarin results in increased expression of DPYSL2 mRNA CTD PMID:20493250 NCBI chr 8:26,514,031...26,658,175
Ensembl chr 8:26,514,031...26,658,178 		JBrowse link
G DSTN destrin, actin depolymerizing factor decreases expression ISO Warfarin results in decreased expression of DSTN mRNA CTD PMID:20493250 NCBI chr20:17,570,075...17,609,919
Ensembl chr20:17,570,075...17,609,919 		JBrowse link
G EEF2 eukaryotic translation elongation factor 2 decreases expression ISO Warfarin results in decreased expression of EEF2 mRNA CTD PMID:20493250 NCBI chr19:3,976,056...3,985,463
Ensembl chr19:3,976,056...3,985,463 		JBrowse link
G EIF3I eukaryotic translation initiation factor 3 subunit I decreases expression ISO Warfarin results in decreased expression of EIF3I mRNA CTD PMID:20493250 NCBI chr 1:32,222,407...32,236,170
Ensembl chr 1:32,221,077...32,245,397 		JBrowse link
G EMCN endomucin decreases expression EXP Warfarin results in decreased expression of EMCN protein CTD PMID:26206560 NCBI chr 4:100,395,341...100,518,022
Ensembl chr 4:100,395,341...100,880,126 		JBrowse link
G ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 increases expression ISO Warfarin results in increased expression of ENPP1 mRNA; Warfarin results in increased expression of ENPP1 protein CTD PMID:22659116 NCBI chr 6:131,808,020...131,895,155
Ensembl chr 6:131,808,016...131,895,155 		JBrowse link
G EPHA7 EPH receptor A7 affects response to substance EXP EPHA7 promoter SNP affects the susceptibility to Warfarin CTD PMID:30357299 NCBI chr 6:93,240,020...93,419,559
Ensembl chr 6:93,240,020...93,419,687 		JBrowse link
G EPHX1 epoxide hydrolase 1 increases response to substance
affects response to substance		 EXP EPHX1 protein results in increased susceptibility to Warfarin
EPHX1 gene polymorphism affects the susceptibility to Warfarin; EPHX1 gene SNP affects the susceptibility to Warfarin; EPHX1 intron SNP affects the susceptibility to Warfarin; EPHX1 polymorphism affects the susceptibility to Warfarin; EPHX1 SNP affects the susceptibility to Warfarin		 CTD PMID:15900282 PMID:17496169 PMID:20842355 PMID:21192345 PMID:24092646 More... NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563 		JBrowse link
G ERP29 endoplasmic reticulum protein 29 decreases expression ISO Warfarin results in decreased expression of ERP29 mRNA CTD PMID:20493250 NCBI chr12:112,013,426...112,023,449
Ensembl chr12:112,013,348...112,023,449 		JBrowse link
G F10 coagulation factor X decreases activity ISO Warfarin results in decreased activity of F10 protein CTD PMID:3490277 PMID:20371969 NCBI chr13:113,122,799...113,149,529
Ensembl chr13:113,122,799...113,149,529 		JBrowse link
G F2 coagulation factor II, thrombin multiple interactions
affects response to substance
decreases expression
decreases activity		 EXP
ISO		 Fenofibrate promotes the reaction [Warfarin results in decreased expression of F2 protein]
F2 gene polymorphism affects the susceptibility to Warfarin
Warfarin results in decreased activity of F2 protein		 CTD PMID:3490277 PMID:9681093 PMID:14656880 NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506 		JBrowse link
G F5 coagulation factor V affects response to substance
decreases activity		 EXP
ISO		 F5 gene polymorphism affects the susceptibility to Warfarin; F5 protein affects the susceptibility to Warfarin
Warfarin results in decreased activity of F5 protein		 CTD PMID:3490277 PMID:19752777 NCBI chr 1:169,511,951...169,586,481
Ensembl chr 1:169,511,951...169,586,588 		JBrowse link
G F7 coagulation factor VII affects response to substance
decreases expression
multiple interactions
decreases activity		 EXP
ISO		 F7 gene mutant form affects the susceptibility to Warfarin; F7 gene polymorphism affects the susceptibility to Warfarin
Warfarin results in decreased expression of F7 protein
Fenofibrate promotes the reaction [Warfarin results in decreased expression of F7 protein]
Warfarin results in decreased activity of F7 protein		 CTD PMID:3490277 PMID:9681093 PMID:14656880 PMID:20371969 PMID:20885134 NCBI chr13:113,105,788...113,120,685
Ensembl chr13:113,105,788...113,120,685 		JBrowse link
G F9 coagulation factor IX decreases activity
increases response to substance		 ISO
EXP		 Warfarin results in decreased activity of F9 protein
F9 gene alternative form results in increased susceptibility to Warfarin		 CTD PMID:3490277 PMID:29450643 NCBI chr  X:139,530,739...139,563,459
Ensembl chr  X:139,530,739...139,563,459 		JBrowse link
G FABP1 fatty acid binding protein 1 multiple interactions ISO Warfarin inhibits the reaction [3-(p-azidobenzyl)-4-hydroxycoumarin binds to Fabp1 protein] RGD PMID:1939124 RGD:1626448 NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062 		JBrowse link
G FGF5 fibroblast growth factor 5 affects response to substance EXP FGF5 gene affects the susceptibility to Warfarin CTD PMID:28686080 NCBI chr 4:80,266,588...80,291,017
Ensembl chr 4:80,266,639...80,336,680 		JBrowse link
G FPGS folylpolyglutamate synthase affects response to substance EXP FPGS gene polymorphism affects the susceptibility to Warfarin CTD PMID:25079360 NCBI chr 9:127,802,858...127,814,506
Ensembl chr 9:127,794,597...127,814,494 		JBrowse link
G FSCN1 fascin actin-bundling protein 1 decreases expression ISO Warfarin results in decreased expression of FSCN1 mRNA CTD PMID:20493250 NCBI chr 7:5,592,816...5,606,655
Ensembl chr 7:5,592,816...5,606,655 		JBrowse link
G G3BP1 G3BP stress granule assembly factor 1 increases expression ISO Warfarin results in increased expression of G3BP1 mRNA CTD PMID:20493250 NCBI chr 5:151,771,954...151,812,785
Ensembl chr 5:151,771,045...151,812,911 		JBrowse link
G GAL3ST1 galactose-3-O-sulfotransferase 1 increases expression ISO Warfarin results in increased expression of GAL3ST1 mRNA CTD PMID:27397090 NCBI chr22:30,554,635...30,574,665
Ensembl chr22:30,554,635...30,574,665 		JBrowse link
G GALE UDP-galactose-4-epimerase decreases expression ISO Warfarin results in decreased expression of GALE mRNA CTD PMID:20493250 NCBI chr 1:23,795,599...23,800,754
Ensembl chr 1:23,795,599...23,800,781 		JBrowse link
G GAS6 growth arrest specific 6 decreases expression
multiple interactions
decreases carboxylation		 ISO
EXP		 Warfarin results in decreased expression of GAS6 protein
[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein]; Warfarin results in decreased activity of and results in decreased carboxylation of GAS6 protein
Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein]
Warfarin results in decreased carboxylation of GAS6 protein		 CTD PMID:9163328 PMID:19564549 PMID:26206560 PMID:27212383 NCBI chr13:113,820,549...113,864,076
Ensembl chr13:113,820,549...113,864,076 		JBrowse link
G GATA4 GATA binding protein 4 affects response to substance EXP GATA4 gene SNP affects the susceptibility to Warfarin CTD PMID:31190750 NCBI chr 8:11,676,935...11,760,002
Ensembl chr 8:11,676,959...11,760,002 		JBrowse link
G GATA6 GATA binding protein 6 affects response to substance EXP GATA6 gene SNP affects the susceptibility to Warfarin CTD PMID:31190750 NCBI chr18:22,169,589...22,202,528
Ensembl chr18:22,169,589...22,202,528 		JBrowse link
G GDI2 GDP dissociation inhibitor 2 increases expression ISO Warfarin results in increased expression of GDI2 mRNA CTD PMID:20493250 NCBI chr10:5,765,223...5,813,434
Ensembl chr10:5,765,222...5,842,132 		JBrowse link
G GFAP glial fibrillary acidic protein increases expression ISO Warfarin results in increased expression of GFAP mRNA; Warfarin results in increased expression of GFAP protein CTD PMID:27397090 NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937 		JBrowse link
G GGCX gamma-glutamyl carboxylase affects response to substance
decreases response to substance
increases response to substance
increases activity		 EXP
ISO		 GGCX gene polymorphism affects the susceptibility to Warfarin; GGCX gene SNP affects the susceptibility to Warfarin; GGCX polymorphism affects the susceptibility to Warfarin
GGCX gene polymorphism results in decreased susceptibility to Warfarin
GGCX protein results in increased susceptibility to Warfarin
Warfarin results in increased activity of GGCX protein		 CTD PMID:3490277 PMID:16676068 PMID:17049586 PMID:17496169 PMID:17764537 More... NCBI chr 2:85,544,720...85,561,493
Ensembl chr 2:85,544,720...85,561,532 		JBrowse link
G GMPS guanine monophosphate synthase increases expression ISO Warfarin results in increased expression of GMPS mRNA CTD PMID:20493250 NCBI chr 3:155,869,430...155,944,020
Ensembl chr 3:155,870,650...155,944,020 		JBrowse link
G GPRC6A G protein-coupled receptor class C group 6 member A multiple interactions ISO Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GPRC6A mRNA] CTD PMID:27488359 NCBI chr 6:116,792,085...116,829,240
Ensembl chr 6:116,792,085...116,829,083 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta multiple interactions ISO [Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein] CTD PMID:23117658 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G HDAC1 histone deacetylase 1 increases expression ISO Warfarin results in increased expression of HDAC1 mRNA CTD PMID:20493250 NCBI chr 1:32,292,083...32,333,626
Ensembl chr 1:32,292,083...32,333,635 		JBrowse link
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions EXP epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] CTD PMID:36162953 NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259 		JBrowse link
G HINT1 histidine triad nucleotide binding protein 1 increases expression ISO Warfarin results in increased expression of HINT1 mRNA CTD PMID:20493250 NCBI chr 5:131,159,027...131,165,256
Ensembl chr 5:131,155,383...131,224,468 		JBrowse link
G HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of HMGCR mRNA] CTD PMID:27488359 NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001 		JBrowse link
G HMOX1 heme oxygenase 1 affects expression ISO Warfarin affects the expression of HMOX1 mRNA CTD PMID:22954530 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214 		JBrowse link
G HNRNPAB heterogeneous nuclear ribonucleoprotein A/B increases expression ISO Warfarin results in increased expression of HNRNPAB mRNA CTD PMID:20493250 NCBI chr 5:178,204,533...178,211,163
Ensembl chr 5:178,204,533...178,211,163 		JBrowse link
G HNRNPDL heterogeneous nuclear ribonucleoprotein D like decreases expression ISO Warfarin results in decreased expression of HNRNPDL mRNA CTD PMID:20493250 NCBI chr 4:82,422,564...82,430,462
Ensembl chr 4:82,422,565...82,430,462 		JBrowse link
G HNRNPF heterogeneous nuclear ribonucleoprotein F increases expression ISO Warfarin results in increased expression of HNRNPF mRNA CTD PMID:20493250 NCBI chr10:43,385,618...43,409,186
Ensembl chr10:43,385,617...43,409,186 		JBrowse link
G HNRNPK heterogeneous nuclear ribonucleoprotein K increases expression
decreases expression		 ISO Warfarin results in increased expression of HNRNPK mRNA
Warfarin results in decreased expression of HNRNPK mRNA		 CTD PMID:20493250 NCBI chr 9:83,968,083...83,980,615
Ensembl chr 9:83,968,083...83,980,631 		JBrowse link
G HP haptoglobin increases expression ISO Warfarin results in increased expression of HP protein CTD PMID:22342526 NCBI chr16:72,054,505...72,061,055
Ensembl chr16:72,054,505...72,061,055 		JBrowse link
G HSP90AB1 heat shock protein 90 alpha family class B member 1 decreases expression ISO Warfarin results in decreased expression of HSP90AB1 mRNA CTD PMID:20493250 NCBI chr 6:44,246,194...44,253,883
Ensembl chr 6:44,246,166...44,253,888 		JBrowse link
G HSPA8 heat shock protein family A (Hsp70) member 8 increases expression ISO Warfarin results in increased expression of HSPA8 mRNA CTD PMID:20493250 NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230 		JBrowse link
G HSPD1 heat shock protein family D (Hsp60) member 1 increases expression ISO Warfarin results in increased expression of HSPD1 mRNA CTD PMID:20493250 NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737 		JBrowse link
G IL12A interleukin 12A increases expression ISO Warfarin results in increased expression of IL12A mRNA CTD PMID:22342526 NCBI chr 3:159,988,835...159,996,019
Ensembl chr 3:159,988,835...159,996,019 		JBrowse link
G IL12B interleukin 12B increases expression ISO Warfarin results in increased expression of IL12B mRNA CTD PMID:22342526 NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863 		JBrowse link
G IL1B interleukin 1 beta multiple interactions
decreases expression		 EXP
ISO		 Warfarin inhibits the reaction [Vitamin K 2 results in decreased susceptibility to IL1B protein]
[Warfarin co-treated with Vitamin K] results in increased expression of IL1B mRNA
Warfarin results in decreased expression of IL1B mRNA		 CTD PMID:20460758 PMID:23117658 PMID:29594315 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL2 interleukin 2 multiple interactions EXP [Warfarin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725 		JBrowse link
G IL6 interleukin 6 increases expression
decreases expression
decreases secretion
multiple interactions		 ISO Warfarin results in increased expression of IL6 protein
Warfarin results in decreased expression of IL6 protein
Warfarin results in decreased expression of IL6 mRNA
Warfarin results in decreased secretion of IL6 protein
[Warfarin co-treated with Vitamin K] results in increased expression of IL6 mRNA		 CTD PMID:18772604 PMID:22342526 PMID:23117658 PMID:26742017 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G INS-IGF2 INS-IGF2 readthrough multiple interactions
increases secretion		 ISO Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased secretion of INS1 protein]
Warfarin results in increased secretion of INS1 protein		 CTD PMID:27488359 NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209 		JBrowse link
G IPO5 importin 5 decreases expression ISO Warfarin results in decreased expression of IPO5 mRNA CTD PMID:20493250 NCBI chr13:97,953,675...98,024,296
Ensembl chr13:97,953,658...98,024,296 		JBrowse link
G ISYNA1 inositol-3-phosphate synthase 1 increases expression ISO Warfarin results in increased expression of ISYNA1 mRNA CTD PMID:20493250 NCBI chr19:18,434,388...18,438,133
Ensembl chr19:18,434,388...18,438,167 		JBrowse link
G KRT18 keratin 18 decreases expression ISO Warfarin results in decreased expression of KRT18 mRNA CTD PMID:20493250 NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906 		JBrowse link
G LASP1 LIM and SH3 protein 1 decreases expression ISO Warfarin results in decreased expression of LASP1 mRNA CTD PMID:20493250 NCBI chr17:38,870,058...38,921,770
Ensembl chr17:38,869,859...38,921,770 		JBrowse link
G LRP1 LDL receptor related protein 1 affects response to substance EXP LRP1 gene SNP affects the susceptibility to Warfarin CTD PMID:32282500 NCBI chr12:57,128,483...57,213,361
Ensembl chr12:57,128,483...57,213,361 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions EXP epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein] CTD PMID:36162953 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions EXP epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein] CTD PMID:36162953 NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MGP matrix Gla protein multiple interactions
decreases carboxylation		 ISO [[Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein] which results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased expression of MGP mRNA
[Quercetin co-treated with Warfarin] results in decreased carboxylation of MGP protein; [Vitamin K co-treated with Warfarin] results in increased carboxylation of MGP protein; Warfarin inhibits the reaction [Vitamin K 1 results in increased expression of and results in increased secretion of MGP protein modified form]; Warfarin results in decreased expression of and results in decreased secretion of MGP protein; Warfarin results in decreased expression of and results in decreased secretion of MGP protein modified form
Warfarin results in decreased carboxylation of MGP protein		 CTD PMID:21705322 PMID:23223575 PMID:23990204 NCBI chr12:14,880,864...14,885,854
Ensembl chr12:14,880,864...14,885,857 		JBrowse link
G MIR133A2 microRNA 133a-2 affects response to substance EXP MIR133A2 gene SNP affects the susceptibility to Warfarin CTD PMID:26113018 NCBI chr20:62,564,912...62,565,013
Ensembl chr20:62,564,912...62,565,013 		JBrowse link
G MPO myeloperoxidase increases activity ISO Warfarin results in increased activity of MPO protein CTD PMID:26742017 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935 		JBrowse link
G MYH1 myosin heavy chain 1 multiple interactions ISO [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of MYH1 mRNA CTD PMID:23117658 NCBI chr17:10,492,307...10,518,542
Ensembl chr17:10,492,307...10,518,542 		JBrowse link
G MYH6 myosin heavy chain 6 affects response to substance EXP MYH6 polymorphism affects the susceptibility to Warfarin CTD PMID:34515533 NCBI chr14:23,381,987...23,408,273
Ensembl chr14:23,381,982...23,408,273 		JBrowse link
G NEDD4 NEDD4 E3 ubiquitin protein ligase affects response to substance EXP NEDD4 gene SNP affects the susceptibility to Warfarin CTD PMID:27488176 NCBI chr15:55,826,917...55,993,612
Ensembl chr15:55,826,922...55,993,660 		JBrowse link
G NMRAL1 NmrA like redox sensor 1 increases expression ISO Warfarin results in increased expression of NMRAL1 mRNA CTD PMID:20493250 NCBI chr16:4,461,694...4,476,337
Ensembl chr16:4,461,691...4,495,763 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 affects response to substance EXP NQO1 gene SNP affects the susceptibility to Warfarin; NQO1 polymorphism affects the susceptibility to Warfarin CTD PMID:23215885 PMID:26257249 PMID:27581200 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions
decreases expression		 EXP [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA; [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Warfarin binds to and results in increased activity of NR1I2 protein
Warfarin results in decreased expression of NR1I2 mRNA		 CTD PMID:20735727 PMID:30963258 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487 		JBrowse link
G NUCB1 nucleobindin 1 increases expression ISO Warfarin results in increased expression of NUCB1 mRNA CTD PMID:20493250 NCBI chr19:48,900,312...48,923,372
Ensembl chr19:48,900,050...48,923,473 		JBrowse link
G NUMB NUMB endocytic adaptor protein multiple interactions ISO [Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA] CTD PMID:23117658 NCBI chr14:73,275,216...73,458,546
Ensembl chr14:73,275,107...73,466,167 		JBrowse link
G OAT ornithine aminotransferase decreases expression ISO Warfarin results in decreased expression of OAT mRNA CTD PMID:20493250 NCBI chr10:124,397,303...124,418,923
Ensembl chr10:124,397,303...124,418,976 		JBrowse link
G ORM1 orosomucoid 1 multiple interactions
affects response to substance
increases response to substance
affects binding		 EXP Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Dipyridamole inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Lidocaine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Progesterone inhibits the reaction [Warfarin binds to ORM1 protein alternative form]
ORM1 gene polymorphism affects the susceptibility to Warfarin; ORM1 polymorphism affects the susceptibility to Warfarin
ORM1 protein results in increased susceptibility to Warfarin		 CTD PMID:8946472 PMID:17496169 PMID:23208322 PMID:26644206 NCBI chr 9:114,323,098...114,326,479
Ensembl chr 9:114,323,098...114,326,479 		JBrowse link
G PA2G4 proliferation-associated 2G4 increases expression ISO Warfarin results in increased expression of PA2G4 mRNA CTD PMID:20493250 NCBI chr12:56,104,559...56,113,910
Ensembl chr12:56,104,537...56,113,910 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases expression EXP Warfarin results in increased expression of PARP1 protein modified form CTD PMID:26206560 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PDGFB platelet derived growth factor subunit B decreases expression ISO Warfarin results in decreased expression of PDGFB mRNA; Warfarin results in decreased expression of PDGFB protein CTD PMID:11290560 NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982 		JBrowse link
G PDIA3 protein disulfide isomerase family A member 3 increases expression
decreases expression		 ISO Warfarin results in increased expression of PDIA3 mRNA
Warfarin results in decreased expression of PDIA3 mRNA		 CTD PMID:20493250 NCBI chr15:43,746,438...43,773,278
Ensembl chr15:43,746,394...43,773,279 		JBrowse link
G PDIA4 protein disulfide isomerase family A member 4 decreases expression ISO Warfarin results in decreased expression of PDIA4 mRNA CTD PMID:20493250 NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662 		JBrowse link
G PGAM1 phosphoglycerate mutase 1 decreases expression
increases expression		 ISO Warfarin results in decreased expression of PGAM1 mRNA
Warfarin results in increased expression of PGAM1 mRNA		 CTD PMID:20493250 NCBI chr10:97,426,191...97,433,444
Ensembl chr10:97,426,191...97,433,444 		JBrowse link
G PKM pyruvate kinase M1/2 decreases expression ISO Warfarin results in decreased expression of PKM mRNA CTD PMID:20493250 NCBI chr15:72,199,029...72,231,591
Ensembl chr15:72,199,029...72,231,819 		JBrowse link
G PLP1 proteolipid protein 1 increases expression ISO Warfarin results in increased expression of PLP1 mRNA CTD PMID:27397090 NCBI chr  X:103,776,506...103,792,619
Ensembl chr  X:103,773,718...103,792,619 		JBrowse link
G POR cytochrome p450 oxidoreductase affects response to substance EXP POR gene SNP affects the susceptibility to Warfarin CTD PMID:27488389 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855 		JBrowse link
G PPP1CA protein phosphatase 1 catalytic subunit alpha decreases expression ISO Warfarin results in decreased expression of PPP1CA mRNA CTD PMID:20493250 NCBI chr11:67,398,183...67,401,858
Ensembl chr11:67,398,181...67,421,183 		JBrowse link
G PPP2R1A protein phosphatase 2 scaffold subunit Aalpha increases expression ISO Warfarin results in increased expression of PPP2R1A mRNA CTD PMID:20493250 NCBI chr19:52,190,052...52,229,518
Ensembl chr19:52,170,936...52,229,518 		JBrowse link
G PROC protein C, inactivator of coagulation factors Va and VIIIa increases response to substance
affects response to substance		 EXP PROC protein results in increased susceptibility to Warfarin
PROC gene polymorphism affects the susceptibility to Warfarin		 CTD PMID:17048007 PMID:17496169 NCBI chr 2:127,418,427...127,429,242
Ensembl chr 2:127,418,427...127,429,242 		JBrowse link
G PROS1 protein S affects response to substance EXP PROS1 gene polymorphism affects the susceptibility to Warfarin; PROS1 protein affects the susceptibility to Warfarin CTD PMID:19752777 NCBI chr 3:93,873,051...93,973,896
Ensembl chr 3:93,873,051...93,980,003 		JBrowse link
G PRSS53 serine protease 53 affects response to substance EXP PRSS53 gene SNP affects the susceptibility to Warfarin CTD PMID:21590310 NCBI chr16:31,083,437...31,088,943
Ensembl chr16:31,083,437...31,089,628 		JBrowse link
G PSMA3 proteasome 20S subunit alpha 3 decreases expression ISO Warfarin results in decreased expression of PSMA3 mRNA CTD PMID:20493250 NCBI chr14:58,244,843...58,272,004
Ensembl chr14:58,244,843...58,272,012 		JBrowse link
G PSMA6 proteasome 20S subunit alpha 6 decreases expression ISO Warfarin results in decreased expression of PSMA6 mRNA CTD PMID:20493250 NCBI chr14:35,278,558...35,317,493
Ensembl chr14:35,278,633...35,317,493 		JBrowse link
G PSMC2 proteasome 26S subunit, ATPase 2 decreases expression ISO Warfarin results in decreased expression of PSMC2 mRNA CTD PMID:20493250 NCBI chr 7:103,347,524...103,369,395
Ensembl chr 7:103,328,570...103,370,346 		JBrowse link
G PTH parathyroid hormone decreases activity ISO Warfarin results in decreased activity of PTH protein CTD PMID:11564701 NCBI chr11:13,492,054...13,496,181
Ensembl chr11:13,492,054...13,496,181 		JBrowse link
G RAB1A RAB1A, member RAS oncogene family decreases expression ISO Warfarin results in decreased expression of RAB1A mRNA CTD PMID:20493250 NCBI chr 2:65,086,854...65,130,106
Ensembl chr 2:65,070,696...65,130,331 		JBrowse link
G RHOA ras homolog family member A decreases expression ISO Warfarin results in decreased expression of RHOA mRNA CTD PMID:20493250 NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998 		JBrowse link
G RPL27 ribosomal protein L27 increases expression ISO Warfarin results in increased expression of RPL27 mRNA CTD PMID:20493250 NCBI chr17:42,998,273...43,002,959
Ensembl chr17:42,998,273...43,002,959 		JBrowse link
G RPL9 ribosomal protein L9 increases expression ISO Warfarin results in increased expression of RPL9 mRNA CTD PMID:20493250 NCBI chr 4:39,454,124...39,458,922
Ensembl chr 4:39,452,587...39,458,931 		JBrowse link
G RPLP0 ribosomal protein lateral stalk subunit P0 increases expression ISO Warfarin results in increased expression of RPLP0 mRNA CTD PMID:20493250 NCBI chr12:120,196,699...120,201,111
Ensembl chr12:120,196,699...120,201,235 		JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 multiple interactions EXP epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RPS6KB1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RPS6KB1 protein] CTD PMID:36162953 NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574 		JBrowse link
G RPSA ribosomal protein SA increases expression ISO Warfarin results in increased expression of RPSA mRNA CTD PMID:20493250 NCBI chr 3:39,406,720...39,412,542
Ensembl chr 3:39,406,716...39,426,255 		JBrowse link
G RUNX1 RUNX family transcription factor 1 multiple interactions
increases expression		 ISO Quercetin inhibits the reaction [Warfarin results in increased expression of RUNX1 mRNA] CTD PMID:23223575 NCBI chr21:34,787,801...35,049,302
Ensembl chr21:34,787,801...36,004,667 		JBrowse link
G RUNX2 RUNX family transcription factor 2 multiple interactions ISO Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]
[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein; [Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA]		 CTD PMID:21910061 PMID:23117658 PMID:27412937 NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349 		JBrowse link
G RUVBL2 RuvB like AAA ATPase 2 decreases expression ISO Warfarin results in decreased expression of RUVBL2 mRNA CTD PMID:20493250 NCBI chr19:48,993,448...49,015,995
Ensembl chr19:48,993,562...49,015,970 		JBrowse link
G SAE1 SUMO1 activating enzyme subunit 1 decreases expression ISO Warfarin results in decreased expression of SAE1 mRNA CTD PMID:20493250 NCBI chr19:47,130,835...47,210,636
Ensembl chr19:47,113,274...47,210,636 		JBrowse link
G SEPHS1 selenophosphate synthetase 1 increases expression ISO Warfarin results in increased expression of SEPHS1 mRNA CTD PMID:20493250 NCBI chr10:13,317,428...13,348,293
Ensembl chr10:13,317,428...13,348,298 		JBrowse link
G SERPINC1 serpin family C member 1 increases expression EXP Warfarin results in increased expression of SERPINC1 protein CTD PMID:73932 NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327 		JBrowse link
G SLC15A2 solute carrier family 15 member 2 affects response to substance EXP SLC15A2 gene SNP affects the susceptibility to Warfarin CTD PMID:29234073 NCBI chr 3:121,894,401...121,944,188
Ensembl chr 3:121,894,401...121,944,188 		JBrowse link
G SLCO1B3 solute carrier organic anion transporter family member 1B3 affects response to substance EXP SLCO1B3 gene SNP affects the susceptibility to Warfarin CTD PMID:29234073 NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911 		JBrowse link
G SOST sclerostin affects response to substance ISO SOST affects the susceptibility to Warfarin CTD PMID:35038187 NCBI chr17:43,753,738...43,758,791
Ensembl chr17:43,753,738...43,758,791 		JBrowse link
G SOX5 SRY-box transcription factor 5 decreases expression
affects localization		 ISO Warfarin results in decreased expression of SOX5 mRNA; Warfarin results in decreased expression of SOX5 protein
Warfarin affects the localization of SOX5 protein		 CTD PMID:34520801 NCBI chr12:23,529,504...24,562,650
Ensembl chr12:23,529,504...24,562,544 		JBrowse link
G SOX9 SRY-box transcription factor 9 multiple interactions
affects localization		 ISO leptomycin B inhibits the reaction [Warfarin affects the localization of SOX9 protein] CTD PMID:34520801 NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416 		JBrowse link
G SP7 Sp7 transcription factor multiple interactions ISO Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] CTD PMID:21910061 NCBI chr12:53,326,575...53,344,793
Ensembl chr12:53,326,575...53,345,315 		JBrowse link
G SPP1 secreted phosphoprotein 1 multiple interactions ISO [Warfarin co-treated with Vitamin K 1] results in increased expression of SPP1 mRNA
[Quercetin co-treated with Warfarin] results in increased expression of SPP1 mRNA; [Warfarin co-treated with Vitamin K] results in increased expression of SPP1 mRNA		 CTD PMID:23117658 PMID:23223575 PMID:23990204 NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532 		JBrowse link
G STIP1 stress induced phosphoprotein 1 decreases expression ISO Warfarin results in decreased expression of STIP1 mRNA CTD PMID:20493250 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543 		JBrowse link
G TAGLN transgelin multiple interactions ISO [Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA
[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA		 CTD PMID:23117658 PMID:23990204 NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464 		JBrowse link
G TCF4 transcription factor 4 increases expression
multiple interactions		 ISO Warfarin results in increased expression of TCF4 mRNA
[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of TCF4 mRNA]		 CTD PMID:23117658 NCBI chr18:55,222,185...55,635,957
Ensembl chr18:55,222,185...55,664,787 		JBrowse link
G TCP1 t-complex 1 increases expression ISO Warfarin results in increased expression of TCP1 mRNA CTD PMID:20493250 NCBI chr 6:159,778,498...159,789,602
Ensembl chr 6:159,778,498...159,789,703 		JBrowse link
G TGM2 transglutaminase 2 affects response to substance
increases response to substance
multiple interactions		 ISO [TGM2 protein affects the susceptibility to Warfarin] which affects the susceptibility to Quercetin; TGM2 protein affects the susceptibility to Warfarin
TGM2 protein results in increased susceptibility to Warfarin
[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein]; Quercetin inhibits the reaction [Warfarin results in increased activity of TGM2 protein]; Warfarin results in increased expression of and results in increased activity of TGM2 protein		 CTD PMID:23117658 NCBI chr20:38,127,385...38,168,475
Ensembl chr20:38,127,385...38,166,578 		JBrowse link
G THOP1 thimet oligopeptidase 1 increases expression ISO Warfarin results in increased expression of THOP1 mRNA CTD PMID:20493250 NCBI chr19:2,785,503...2,815,807
Ensembl chr19:2,785,503...2,815,807 		JBrowse link
G TNF tumor necrosis factor decreases expression
decreases secretion
multiple interactions
increases expression		 ISO Warfarin results in decreased expression of TNF mRNA
Warfarin results in decreased secretion of TNF protein
[Warfarin co-treated with Vitamin K] results in increased expression of TNF mRNA
Warfarin results in increased expression of TNF		 CTD PMID:21565690 PMID:22342526 PMID:23117658 PMID:26742017 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TP53 tumor protein p53 increases degradation
increases expression		 EXP
ISO		 Warfarin results in increased degradation of TP53 protein
Warfarin results in increased expression of TRP53 mRNA; Warfarin results in increased expression of TRP53 protein		 CTD PMID:14634213 PMID:29358327 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546 		JBrowse link
G TUBA1A tubulin alpha 1a increases expression ISO Warfarin results in increased expression of TUBA1A mRNA CTD PMID:20493250 NCBI chr12:49,184,795...49,189,080
Ensembl chr12:49,184,686...49,189,324 		JBrowse link
G TUBA1B tubulin alpha 1b increases expression
decreases expression		 ISO Warfarin results in increased expression of TUBA1B mRNA
Warfarin results in decreased expression of TUBA1B mRNA		 CTD PMID:20493250 NCBI chr12:49,127,782...49,131,395
Ensembl chr12:49,127,782...49,131,397 		JBrowse link
G TUBB tubulin beta class I decreases expression ISO Warfarin results in decreased expression of TUBB5 mRNA CTD PMID:20493250 NCBI chr 6:30,720,352...30,725,422
Ensembl chr 6:30,717,435...30,725,538 		JBrowse link
G TUFM Tu translation elongation factor, mitochondrial decreases expression ISO Warfarin results in decreased expression of TUFM mRNA CTD PMID:20493250 NCBI chr16:28,842,411...28,846,348
Ensembl chr16:28,842,411...28,846,348 		JBrowse link
G TYRO3 TYRO3 protein tyrosine kinase decreases expression ISO Warfarin results in decreased expression of TYRO3 mRNA CTD PMID:18772604 PMID:27397090 NCBI chr15:41,559,212...41,583,589
Ensembl chr15:41,557,675...41,583,589 		JBrowse link
G U2AF2 U2 small nuclear RNA auxiliary factor 2 increases expression ISO Warfarin results in increased expression of U2AF2 mRNA CTD PMID:20493250 NCBI chr19:55,655,035...55,674,716
Ensembl chr19:55,654,146...55,674,716 		JBrowse link
G UGT1A1 UDP glucuronosyltransferase family 1 member A1 multiple interactions
increases metabolic processing
affects response to substance		 EXP [UGT1A1 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of Glucuronides; [Warfarin binds to and results in decreased activity of UGT1A1 protein] which results in decreased glucuronidation of Estradiol; Warfarin binds to and results in decreased activity of UGT1A1 protein; Warfarin inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Estradiol]
UGT1A1 gene SNP affects the susceptibility to Warfarin; UGT1A1 polymorphism affects the susceptibility to Warfarin		 CTD PMID:19408964 PMID:25312789 PMID:25393417 PMID:26223945 NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300 		JBrowse link
G UGT1A10 UDP glucuronosyltransferase family 1 member A10 multiple interactions
increases metabolic processing		 EXP [UGT1A10 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of Glucuronides CTD PMID:19408964 NCBI chr 2:233,636,448...233,773,300
Ensembl chr 2:233,636,448...233,773,300 		JBrowse link
G UGT1A3 UDP glucuronosyltransferase family 1 member A3 multiple interactions EXP [Warfarin binds to and results in increased activity of UGT1A3 protein] which results in increased glucuronidation of vorinostat; Warfarin binds to and results in increased activity of UGT1A3 protein; Warfarin promotes the reaction [UGT1A3 protein results in increased glucuronidation of vorinostat] CTD PMID:25393417 NCBI chr 2:233,729,042...233,773,300
Ensembl chr 2:233,729,042...233,773,300 		JBrowse link
G UGT1A7 UDP glucuronosyltransferase family 1 member A7 multiple interactions EXP [Warfarin binds to and affects the activity of UGT1A7 protein] which affects the glucuronidation of Hymecromone; Warfarin affects the reaction [UGT1A7 protein results in increased glucuronidation of Hymecromone]; Warfarin binds to and affects the activity of UGT1A7 protein CTD PMID:25393417 NCBI chr 2:233,681,901...233,773,300
Ensembl chr 2:233,681,901...233,773,300 		JBrowse link
G UGT1A9 UDP glucuronosyltransferase family 1 member A9 multiple interactions EXP [Warfarin binds to and affects the activity of UGT1A9 protein] which affects the glucuronidation of Propofol; Warfarin affects the reaction [UGT1A9 protein results in increased glucuronidation of Propofol]; Warfarin binds to and affects the activity of UGT1A9 protein CTD PMID:25393417 NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300 		JBrowse link
G UGT2B17 UDP glucuronosyltransferase family 2 member B17 multiple interactions EXP [Warfarin binds to and results in decreased activity of UGT2B17 protein] which results in decreased glucuronidation of vorinostat; Warfarin binds to and results in decreased activity of UGT2B17 protein; Warfarin inhibits the reaction [UGT2B17 protein results in increased glucuronidation of vorinostat] CTD PMID:25393417 NCBI chr 4:68,537,173...68,576,322
Ensembl chr 4:68,537,173...68,576,413 		JBrowse link
G UGT2B7 UDP glucuronosyltransferase family 2 member B7 multiple interactions EXP [Warfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine; Warfarin binds to and results in decreased activity of UGT2B7 protein; Warfarin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Zidovudine] CTD PMID:25393417 NCBI chr 4:69,051,375...69,112,987
Ensembl chr 4:69,051,363...69,112,987 		JBrowse link
G USP5 ubiquitin specific peptidase 5 decreases expression ISO Warfarin results in decreased expression of USP5 mRNA CTD PMID:20493250 NCBI chr12:6,852,150...6,866,632
Ensembl chr12:6,852,148...6,866,632 		JBrowse link
G VCP valosin containing protein decreases expression
increases expression		 ISO Warfarin results in decreased expression of VCP mRNA
Warfarin results in increased expression of VCP mRNA		 CTD PMID:20493250 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,053,928...35,072,668 		JBrowse link
G VDR vitamin D receptor affects response to substance EXP VDR gene SNP affects the susceptibility to Warfarin CTD PMID:28262345 PMID:29298995 NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048 		JBrowse link
G VEGFA vascular endothelial growth factor A affects response to substance
multiple interactions		 EXP VEGFA gene SNP affects the susceptibility to Warfarin
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA mRNA]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA protein]		 CTD PMID:31068094 PMID:36162953 NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VIM vimentin decreases expression EXP Warfarin results in decreased expression of VIM protein CTD PMID:26206560 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593 		JBrowse link
G VKORC1 vitamin K epoxide reductase complex subunit 1 multiple interactions
decreases metabolic processing
increases response to substance
affects metabolic processing
decreases response to substance
decreases activity
affects response to substance
affects abundance		 EXP
ISO		 [CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin; Warfarin binds to and results in decreased activity of VKORC1 protein; Warfarin inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide]
VKORC1 gene polymorphism results in decreased metabolism of Warfarin
VKORC1 intron polymorphism results in increased susceptibility to Warfarin; VKORC1 protein results in increased susceptibility to Warfarin; VKORC1 results in increased susceptibility to Warfarin
VKORC1 protein affects the metabolism of Warfarin
VKORC1 gene mutant form results in decreased susceptibility to Warfarin; VKORC1 protein polymorphism results in decreased susceptibility to Warfarin
Warfarin results in decreased activity of VKORC1 protein
VKORC1 protein mutant form affects the susceptibility to Warfarin
Warfarin inhibits the reaction [VKORC1 protein affects the reduction of vitamin K1 oxide]
VKORC1 3' UTR SNP affects the susceptibility to Warfarin; VKORC1 affects the susceptibility to Warfarin; VKORC1 alternative form affects the susceptibility to Warfarin; VKORC1 gene affects the susceptibility to Warfarin; VKORC1 gene mutant form affects the susceptibility to Warfarin; VKORC1 gene polymorphism affects the susceptibility to Warfarin; VKORC1 gene SNP affects the susceptibility to Warfarin; VKORC1 intron polymorphism affects the susceptibility to Warfarin; VKORC1 intron SNP affects the susceptibility to Warfarin; VKORC1 polymorphism affects the susceptibility to Warfarin; VKORC1 promoter polymorphism affects the susceptibility to Warfarin; VKORC1 promoter SNP affects the susceptibility to Warfarin; VKORC1 protein affects the susceptibility to Warfarin; VKORC1 protein polymorphism affects the susceptibility to Warfarin; VKORC1 protein SNP affects the susceptibility to Warfarin; VKORC1 SNP affects the susceptibility to Warfarin
VKORC1 3' UTR results in decreased susceptibility to Warfarin; VKORC1 gene mutant form results in decreased susceptibility to Warfarin; VKORC1 gene polymorphism results in decreased susceptibility to Warfarin
VKORC1 gene polymorphism affects the abundance of Warfarin		 CTD PMID:14765194 PMID:14765195 PMID:15358623 PMID:15578879 PMID:15630486 More... NCBI chr16:31,090,854...31,094,797
Ensembl chr16:31,090,842...31,095,980 		JBrowse link
G VKORC1L1 vitamin K epoxide reductase complex subunit 1 like 1 multiple interactions EXP
ISO		 Warfarin affects the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide]; Warfarin binds to and results in decreased activity of VKORC1L1 protein; Warfarin inhibits the reaction [VKORC1L1 protein results in increased metabolism of vitamin K1 oxide]; Warfarin inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide] CTD PMID:23710884 PMID:23928358 PMID:29581108 NCBI chr 7:65,865,772...65,959,558
Ensembl chr 7:65,873,074...65,959,563 		JBrowse link
G YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon increases expression ISO Warfarin results in increased expression of YWHAE mRNA CTD PMID:20493250 NCBI chr17:1,344,275...1,400,222
Ensembl chr17:1,344,275...1,400,222 		JBrowse link
G ZEB1 zinc finger E-box binding homeobox 1 decreases expression EXP Warfarin results in decreased expression of ZEB1 protein CTD PMID:26206560 NCBI chr10:31,318,417...31,529,804
Ensembl chr10:31,318,495...31,529,814 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26502
    role 26316
      application 25588
        pesticide 21228
          rodenticide 14426
            warfarin 199
Path 2
Term Annotations click to browse term
  CHEBI ontology 26502
    subatomic particle 26470
      composite particle 26478
        hadron 26478
          baryon 26478
            nucleon 26470
              atomic nucleus 26478
                atom 26478
                  main group element atom 26206
                    p-block element atom 26206
                      carbon group element atom 25649
                        carbon atom 25611
                          organic molecular entity 25611
                            organic molecule 25362
                              organic cyclic compound 24410
                                organic heterocyclic compound 22422
                                  oxacycle 20188
                                    benzopyran 12776
                                      1-benzopyran 12514
                                        chromenes 4793
                                          chromenone 4737
                                            coumarins 4499
                                              hydroxycoumarin 365
                                                4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one 199
                                                  (R)-warfarin 199
                                                    warfarin 199
paths to the root